NASDAQ: PBYIPuma Biotechnology Inc Stock
$2.77-0.12 (-4.15%)
Updated Sep 25, 2023
PBYI Price
$2.77
Fair Value Price
$4.07
Market Cap
$131.60M
52 Week Low
$2.08
52 Week High
$5.16
P/E
-46.17x
P/B
4.33x
P/S
0.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$230.12M
Earnings
-$2.44M
Gross Margin
76.4%
Operating Margin
4.83%
Profit Margin
-1.1%
Debt to Equity
5.6
Operating Cash Flow
$31M
Beta
1.18
Next Earnings
Nov 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PBYI Overview
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PBYI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PBYI ($2.77) is undervalued by 31.97% relative to our estimate of its Fair Value price of $4.07 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PBYI ($2.77) is significantly undervalued by 31.97% relative to our estimate of its Fair Value price of $4.07 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PBYI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PBYI due diligence checks available for Premium users.
Be the first to know about important PBYI news, forecast changes, insider trades & much more!
PBYI News
Valuation
PBYI fair value
Fair Value of PBYI stock based on Discounted Cash Flow (DCF)
Price
$2.77
Fair Value
$4.07
Undervalued by
31.97%
PBYI ($2.77) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PBYI ($2.77) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PBYI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PBYI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-46.17x
Industry
12.93x
Market
14.28x
PBYI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.33x
Industry
5.09x
PBYI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PBYI's financial health
Profit margin
Revenue
$54.6M
Net Income
$2.1M
Profit Margin
3.9%
PBYI's Earnings (EBIT) of $11.12M... subscribe to Premium to read more.
Interest Coverage Financials
PBYI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$200.5M
Liabilities
$170.1M
Debt to equity
5.6
PBYI's short-term assets ($118.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PBYI's short-term assets ($118.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PBYI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PBYI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.3M
Investing
-$4.7M
Financing
$0.0
PBYI's operating cash flow ($30.88M)... subscribe to Premium to read more.
Debt Coverage Financials
PBYI vs Biotech Stocks
Puma Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.